2,5-己酮可可碱
2,5-己酮可可碱结构式
|
常用名 | 2,5-己酮可可碱 | 英文名 | DMXAA (Vadimezan) |
|---|---|---|---|---|
| CAS号 | 117570-53-3 | 分子量 | 282.291 | |
| 密度 | 1.3±0.1 g/cm3 | 沸点 | 520.9±50.0 °C at 760 mmHg | |
| 分子式 | C17H14O4 | 熔点 | 264 °C | |
| MSDS | 中文版 美版 | 闪点 | 197.1±23.6 °C | |
| 符号 |
GHS07, GHS09 |
信号词 | Warning |
|
Proteomic response to 5,6-dimethylxanthenone 4-acetic acid (DMXAA, vadimezan) in human non-small cell lung cancer A549 cells determined by the stable-isotope labeling by amino acids in cell culture (SILAC) approach.
Drug Des. Devel. Ther. 9 , 937-68, (2015) 5,6-Dimethylxanthenone 4-acetic acid (DMXAA), also known as ASA404 and vadimezan, is a potent tumor blood vessel-disrupting agent and cytokine inducer used alone or in combination with other cytotoxic agents for the treatment of non-small cell lung cancer (NS... |
|
|
Casein kinase II controls TBK1/IRF3 activation in IFN response against viral infection.
J. Immunol. 194 , 4477-88, (2015) By sensing viral nucleic acids, host innate receptors elicit signaling pathways converging on TBK1-IFN regulatory factor (IRF)3 axis in mediating IFN-αβ induction and defense mechanisms. In contrast, viruses have evolved with diverse immune evasion/interferen... |
|
|
TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN.
Eur. J. Immunol. 45(4) , 1159-69, (2015) Agonists for TLR9 and Stimulator of IFN Gene (STING) act as vaccine adjuvants that induce type-1 immune responses. However, currently available CpG oligodeoxynucleotide (ODN) (K-type) induces IFNs only weakly and STING ligands rather induce type-2 immune resp... |
|
|
SEC-TID: A Label-Free Method for Small-Molecule Target Identification.
J. Biomol. Screen. 19(6) , 917-927, (2014) Bioactive small molecules are an invaluable source of therapeutics and chemical probes for exploring biological pathways. Yet, significant hurdles in drug discovery often come from lacking a comprehensive view of the target(s) for both early tool molecules an... |
|
|
Development of a CD-MEKC method for investigating the metabolism of tamoxifen by flavin-containing monooxygenases and the inhibitory effects of methimazole, nicotine and DMXAA.
Electrophoresis 34(3) , 463-70, (2013) A selective and low-cost CD-MEKC method under acidic conditions was developed for investigating the N-oxygenation of tamoxifen (TAM) by flavin-containing monooxygenases (FMOs). The inhibitory effects of methimazole (MMI), nicotine and 5,6-dimethylxanthenone-4... |
|
|
Vascular disrupting agent drug classes differ in effects on the cytoskeleton.
PLoS ONE 7(7) , e40177, (2012) Vascular disrupting agents (VDAs), anti-cancer drugs that target established tumor blood vessels, fall into two main classes: microtubule targeting drugs, exemplified by combretastatin A4 (CA4), and flavonoids, exemplified by 5,6-dimethylxanthenone-4-acetic a... |
|
|
Monitoring antivascular therapy in head and neck cancer xenografts using contrast-enhanced MR and US imaging.
Angiogenesis 14(4) , 491-501, (2011) The overall goal of this study was to non-invasively monitor changes in blood flow of squamous cell carcinoma of the head and neck (SCCHN) xenografts using contrast-enhanced magnetic resonance (MR) and ultrasound (US) imaging.Experimental studies were perform... |
|
|
Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines.
J. Biomed. Sci. 18 , 21, (2011) Antigen-specific immunotherapy using DNA vaccines has emerged as an attractive approach for the control of tumors. Another novel cancer therapy involves the employment of the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA). In the curr... |
|
|
Aminolevulinic acid-photodynamic therapy combined with topically applied vascular disrupting agent vadimezan leads to enhanced antitumor responses.
Photochem. Photobiol. 87(4) , 910-9, (2011) The tumor vascular-disrupting agent (VDA) vadimezan (5,6-dimethylxanthenone-4-acetic acid, DMXAA) has been shown to potentiate the antitumor activity of photodynamic therapy (PDT) using systemically administered photosensitizers. Here, we characterized the re... |
|
|
p38 mitogen-activated protein kinase is required for the antitumor activity of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid.
J. Pharmacol. Exp. Ther. 341(3) , 709-17, (2012) 5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a potent vascular disrupting agent, selectively destroys established tumor vasculature, causing a rapid collapse in blood flow that ultimately leads to inhibition of tumor growth. Here, we demonstrate that p38 MAP... |